Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

Rocket One Inc.

CIK 1711786 RKTO·Pharmaceutical Preparations · All EDGAR filings ↗

Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

Rocket One Inc. disclosed substantial doubt about its ability to continue as a going concern

Substantial doubt raised, alleviated by management's plans → Substantial doubt about ability to continue as a going concern

If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these unaudited…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2026-08-14
Prior form
10-Q
Prior state
doubt_alleviated
Prior state label
Substantial doubt raised, alleviated by management's plans
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Material weakness Filing comparison

Hoth Therapeutics, Inc. reported internal control effective again after a material weakness

Material weakness in internal control → Internal control reported effective

The weakness was first reported on 2025-03-28 — 364 days and 1 annual report before this one.

Based on this assessment, our management concluded that, as of December 31, 2025, our internal control over financial reporting was effective based on such criteria. Changes in Internal Control Over Financial Reporting Other than as described above, there have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-03-28
Prior form
10-K
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
No
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
1
Weakness days reported
364
Weakness first reported
2025-03-28
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.
Formerly
Hoth Therapeutics, Inc.

Source filing ↗ Prior filing ↗

Going concern Filing comparison

Hoth Therapeutics, Inc. disclosed substantial doubt about its ability to continue as a going concern

Substantial doubt raised, alleviated by management's plans → Substantial doubt about ability to continue as a going concern

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt About the Company’s Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
filing body
Prior filed
2025-03-28
Prior form
10-K
Prior state
doubt_alleviated
Prior state label
Substantial doubt raised, alleviated by management's plans
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.
Formerly
Hoth Therapeutics, Inc.

Source filing ↗ Prior filing ↗